

# Paula González-Ericsson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5407287/publications.pdf>

Version: 2024-02-01

39  
papers

3,071  
citations

257450

24  
h-index

395702

33  
g-index

41  
all docs

41  
docs citations

41  
times ranked

5508  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract PD3-04: Multi-omics characterization of triple-negative breast cancer identifies therapeutic vulnerabilities and epigenetic immune suppression in the mesenchymal subtype. <i>Cancer Research</i> , 2022, 82, PD3-04-PD3-04.	0.9	0
2	Abstract P1-04-03: Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1. <i>Cancer Research</i> , 2022, 82, P1-04-03-P1-04-03.	0.9	0
3	Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer. <i>Cancer Research Communications</i> , 2022, 2, 286-292.	1.7	2
4	Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 829-843.	3.4	12
5	Abstract PS17-14: Evaluating the efficacy of immunotherapy in triple negative breast cancer. , 2021, , .		0
6	Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	11
7	Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4379-4396.	7.0	30
8	Tissue-specific expression of p73 and p63 isoforms in human tissues. <i>Cell Death and Disease</i> , 2021, 12, 745.	6.3	13
9	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5299-5306.	7.0	39
10	Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition. <i>Nature Communications</i> , 2021, 12, 6201.	12.8	57
11	Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. <i>Nature Communications</i> , 2021, 12, 6276.	12.8	89
12	245...Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1. , 2021, 9, A264-A264.		0
13	812...Erythema nodosum-like toxicity in an immunotherapy treated patient is accompanied by oligoclonal memory activated CD4 T cells. , 2021, 9, A848-A848.		1
14	318...Enforced tumor specific MHC-I heterogeneity in triple negative breast cancer drives immunotherapy resistance. , 2021, 9, A342-A342.		1
15	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	5.2	112
16	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2111-2123.	7.0	91
17	Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. <i>Nature Communications</i> , 2020, 11, 5488.	12.8	25
18	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5668-5681.	7.0	37

#	ARTICLE	IF	CITATIONS
19	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	5.2	90
20	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	5.2	106
21	Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	46
22	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	4.5	142
23	Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. <i>Cancer Cell</i> , 2020, 37, 183-199.e5.	16.8	33
24	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. <i>Nature Medicine</i> , 2019, 25, 1243-1250.	30.7	133
25	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 31.	5.2	31
26	p73 regulates epidermal wound healing and induced keratinocyte programming. <i>PLoS ONE</i> , 2019, 14, e0218458.	2.5	20
27	Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations. <i>Molecular Cancer Research</i> , 2019, 17, 1842-1853.	3.4	11
28	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. <i>Nature Communications</i> , 2019, 10, 1373.	12.8	252
29	Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1. <i>Cancer Research</i> , 2019, 79, 171-182.	0.9	57
30	Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 277-289.	7.0	74
31	Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. <i>Clinical Cancer Research</i> , 2019, 25, 771-783.	7.0	29
32	DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. <i>Nature Communications</i> , 2018, 9, 248.	12.8	181
33	Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. <i>Cancer Research</i> , 2018, 78, 1845-1858.	0.9	54
34	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. <i>OncImmunity</i> , 2018, 7, e1438106.	4.6	54
35	Post-irradiation morphea of the breast: a case report and review of the literature. <i>Histopathology</i> , 2018, 72, 342-350.	2.9	18
36	Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers. <i>Cancer Research</i> , 2018, 78, 6183-6195.	0.9	130

#	ARTICLE	IF	CITATIONS
37	Genomic profiling of ER <sup>+</sup> breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	91
38	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 311-335.	4.3	530
39	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	4.3	469